Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Infantile hemangioma with minimal or arrested growth as the skin manifestation of PHACE syndrome.

Valdivielso-Ramos M, Torrelo A, Martin-Santiago A, Campos M, Conde E, de la Cueva P, Lopez-Gutierrez JC.

Pediatr Dermatol. 2018 Jul 9. doi: 10.1111/pde.13597. [Epub ahead of print]

PMID:
29984853
2.

Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis.

Carrascosa JM, Rebollo F, Gómez S, De-la-Cueva P.

J Dermatolog Treat. 2018 May 8:1-6. doi: 10.1080/09546634.2018.1467536. [Epub ahead of print]

PMID:
29671665
3.

Current Status of Multidisciplinary Care in Psoriatic Arthritis in Spain: NEXUS 2.0 Project.

Queiro R, Coto P, Joven B, Rivera R, Navío Marco T, de la Cueva P, Alvarez Vega JL, Narváez Moreno B, Rodriguez Martínez FJ, Pardo Sánchez J, Feced Olmos C, Pujol C, Rodríguez J, Notario J, Pujol Busquets M, García Font M, Galindez E, Pérez Barrio S, Urruticoechea-Arana A, Hergueta M, López Montilla MD, Vélez García-Nieto A, Maceiras F, Rodríguez Pazos L, Rubio Romero E, Rodríguez Fernandez Freire L, Luelmo J, Gratacós J.

Reumatol Clin. 2018 Feb 26. pii: S1699-258X(18)30030-5. doi: 10.1016/j.reuma.2018.01.010. [Epub ahead of print] English, Spanish.

4.

Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain.

Gratacós J, Luelmo J, Rodríguez J, Notario J, Marco TN, de la Cueva P, Busquets MP, Font MG, Joven B, Rivera R, Vega JLA, Álvarez AJC, Parera RS, Carrascosa JCR, Martínez FJR, Sánchez JP, Olmos CF, Pujol C, Galindez E, Barrio SP, Arana AU, Hergueta M, Coto P, Queiro R.

Rheumatol Int. 2018 Jun;38(6):1115-1124. doi: 10.1007/s00296-018-3986-4. Epub 2018 Feb 7.

PMID:
29417210
5.

Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study.

Descalzo MA, Carretero G, Ferrándiz C, Rivera R, Daudén E, Gómez-García FJ, de la Cueva P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Baniandrés O, Carrascosa JM, Llamas-Velasco M, Ruiz-Genao D, Herrera-Acosta E, Muñoz-Santos C, García-Doval I; Biobadaderm Study Group.

J Am Acad Dermatol. 2018 Apr;78(4):798-800. doi: 10.1016/j.jaad.2017.10.051. Epub 2017 Nov 13. No abstract available.

PMID:
29146129
6.

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.

Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vilarrasa E, Del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral F, Armesto S, Eiris N, Mitxelena J, Vilar-Alejo J, A Martin M, Soria C; from the Spanish Group of Psoriasis.

J Dermatolog Treat. 2018 Jun;29(4):334-346. doi: 10.1080/09546634.2017.1395794. Epub 2017 Nov 21. Review.

PMID:
29099667
7.

Moderate Psoriasis: A Proposed Definition.

Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D.

Actas Dermosifiliogr. 2017 Dec;108(10):911-917. doi: 10.1016/j.ad.2017.07.002. Epub 2017 Aug 17. Review. English, Spanish.

PMID:
28823420
8.

Reliability of the MDi Psoriasis® Application to Aid Therapeutic Decision-Making in Psoriasis.

Moreno-Ramírez D, Herrerías-Esteban JM, Ojeda-Vila T, Carrascosa JM, Carretero G, de la Cueva P, Ferrándiz C, Galán M, Rivera R, Rodríguez-Fernández L, Ruiz-Villaverde R, Ferrándiz L.

Actas Dermosifiliogr. 2017 Sep;108(7):650-656. doi: 10.1016/j.ad.2017.02.009. Epub 2017 Apr 4. English, Spanish.

PMID:
28385425
9.

New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.

Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, Baniandrés O, López-Estebaranz JL, de la Cueva P, Daudén E, Abad-Santos F.

Pharmacogenomics J. 2018 Jan;18(1):70-75. doi: 10.1038/tpj.2016.64. Epub 2016 Sep 27.

10.

Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians.

Carrascosa JM, de la Cueva P, Herranz P, Labandeira J, Notario J.

J Dermatolog Treat. 2017 May;28(3):188-199. doi: 10.1080/09546634.2016.1230174. Epub 2016 Sep 19.

PMID:
27569650
11.

Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.

García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D; BIOBADADERM and BIOBADASER study groups.

Br J Dermatol. 2017 Mar;176(3):643-649. doi: 10.1111/bjd.14776. Epub 2016 Oct 3.

PMID:
27258623
12.

Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.

Elías I, Ortega-Joaquín N, de la Cueva P, Del Pozo LJ, Moreno-Ramírez D, Boada A, Aguilar M, Mirada A, Mosquera E, Gibbons C, Oyagüez I.

Actas Dermosifiliogr. 2016 Jul-Aug;107(6):498-508. doi: 10.1016/j.ad.2016.03.004. Epub 2016 Apr 26. English, Spanish.

PMID:
27130804
13.

Multidisciplinary Care Models for Patients With Psoriatic Arthritis.

Queiro R, Coto P, Rodríguez J, Notario J, Navío Marco T, de la Cueva P, Pujol Busquets M, García Font M, Joven B, Rivera R, Alvarez Vega JL, Chaves Álvarez AJ, Sánchez Parera R, Ruiz Carrascosa JC, Rodríguez Martínez FJ, Pardo Sánchez J, Feced Olmos C, Pujol C, Galindez E, Pérez Barrio S, Urruticoechea Arana A, Hergueta M, Luelmo J, Gratacós J.

Reumatol Clin. 2017 Mar - Apr;13(2):85-90. doi: 10.1016/j.reuma.2016.03.005. Epub 2016 Apr 8. English, Spanish.

14.

Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis.

Aterido A, Julià A, Ferrándiz C, Puig L, Fonseca E, Fernández-López E, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno-Ramírez D, Vanaclocha F, Herrera E, de la Cueva P, Dand N, Palau N, Alonso A, López-Lasanta M, Tortosa R, García-Montero A, Codó L, Gelpí JL, Bertranpetit J, Absher D, Capon F, Myers RM, Barker JN, Marsal S.

J Invest Dermatol. 2016 Mar;136(3):593-602. doi: 10.1016/j.jid.2015.11.026. Epub 2015 Dec 29.

15.

Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations.

Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, Ferrándiz L, Sánchez-Carazo JL, Daudén E, López-Estebaranz JL, Vidal D, Herranz P, Jorquera E, Coto-Segura P, Ribera M.

Actas Dermosifiliogr. 2016 Apr;107(3):194-206. doi: 10.1016/j.ad.2015.10.005. Epub 2015 Nov 21. Review. English, Spanish.

PMID:
26614486
16.

Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis.

Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, Baniandrés O, López-Estebaranz JL, de la Cueva P, Daudén E, Abad-Santos F.

J Immunol Res. 2015;2015:101879. doi: 10.1155/2015/101879. Epub 2015 Nov 3.

17.

Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% for Actinic Keratosis Treatment In Spain.

Elias I, Ortega-Joaquin N, Aguilar M, Moreno D, Boada A, Del Pozo LJ, de la Cueva P, Mirada A, Mosquera E, Gibbons C, Oyagüez I.

Value Health. 2015 Nov;18(7):A423-4. doi: 10.1016/j.jval.2015.09.573. Epub 2015 Oct 20. No abstract available.

18.

Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain.

Ortega-Joaquin N, Elías I, de la Cueva P, Del Pozo LJ, Boada A, Moreno D, Aguilar M, Mosquera E, Mirada A, Gibbons C, Oyagüez I.

Value Health. 2015 Nov;18(7):A423. doi: 10.1016/j.jval.2015.09.569. Epub 2015 Oct 20. No abstract available.

19.

The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.

Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, Baniandrés O, López Estebaranz JL, de la Cueva P, Daudén E, Abad-Santos F.

Pharmacogenomics. 2015;16(15):1723-31. doi: 10.2217/pgs.15.107. Epub 2015 Sep 29.

PMID:
26415694
20.

Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.

García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, de la Cueva P, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group.

J Dermatolog Treat. 2016;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25.

PMID:
26367799

Supplemental Content

Loading ...
Support Center